|
|
Article: European Commission Approves Serono's Ovitrelle(R) Solution For Injection In a Pre-Filled Syringe For Treatment of Infertility; Ovitrelle(R) - The World's Only Recombinant, Filled-By-Mass and Consistent hCG Is Now Available in a Ready-To-Use Pre-Filled Syringe That Will Allow Patients to Administer hCG With One Simple Step.
- Article from:
- PR Newswire
- Article date:
- October 30, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Serono S.A. (virt-x: SEO and NYSE: SRA), announced today that the European Commission has approved its new pre-filled syringe for Ovitrelle(R) (choriogonadotropin alfa).
Designed to make infertility treatment easier for patients, the new Ovitrelle(R) Solution for Injection is designed so that patients can administer their r-hCG in one single step. Unlike other hCG treatments, the Ovitrelle(R) Solution for Injection does not require patients to mix medication prior to injection. It is also the only available recombinant version of human chorionic gonadotropin (hCG), one of three hormones required to treat infertility. Essentially equivalent in structure to ...